NCT00017030View on ClinicalTrials.gov

Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

December 31, 2009

Conditions
Sarcoma
Interventions
DRUG

trabectedin

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00017030 - Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter